References
- Clinical Challenges in Schizophrenia: A Six-Part Newsletter Series to Current Psychiatr20112S1S4 Available from: http://www.currentpsychiatry.com/home/article/challenges-and-opportunities-in-schizophrenia-treatment/f5fe98b0f0d1f5ae950fb84f07e42edc.htmlAccessed November 4, 2013
- ZhornitskySStipEOral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic reviewSchizophr Res Treatment2012201240717122966436
- TandonRNasrallahHAKeshavanMSSchizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and futureSchizophr Res201012212320655178
- Invega® Sustenna®Prescribing informationTitusville, NJJanssen Pharmaceuticals Inc2012
- KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol20101363564719941696
- GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
- NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology2010352072208220555312
- PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113521822621092748
- PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
- BanerjeeACross-cultural variance of schizophrenia in symptoms, diagnosis and treatmentGeorgetown Undergraduate Journal of Health Sciences201261824
- CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012122622455454
- WilliamsDREarlTRCommentary: race and mental health – more questions than answersInt J Epidemiol20073675876017566003
- LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry2011351002100821315787
- InadaTEvaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its UsageTokyo, JapanSeiwa Shoten Publishers1996
- PosnerKBrownGKStanleyBThe Columbia-Suicide Severity Rating Scale: initial validity and internal three multisite studies with adolescents and adultsAm J Psychiatry2011168121266127722193671
- GopalSVijapurkarULimPA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol20112568569720615933
- HoughDGopalSVijapurkarUPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res201011610711719959339
- CorrellCUAddressing barriers to using long-acting injectable antipsychotics and appropriately monitoring antipsychotic adverse effectsJ Clin Psychiatry201374e16
- KapurS5-HT2 antagonism and EPS benefits: is there a causal connection?Psychopharmacology (Berl)199612435398935798
- NybergSFardeLHalldinCDahlMLBertilssonLD2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoateAm J Psychiatry19951521731787840348
- KarlssonPDenckerENybergSPharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studiesClin Pharmacol Ther200679P74